The role of short-term metformin in regulating zinc and adipose tissue-derived biomarkers in children with obesity and insulin resistance
Abstract
AIM: To evaluate the short-term effects of metformin treatment on serum zinc (Zn), zinc-α2-glycoprotein (ZAG), peroxisome proliferator-activated receptor gamma (PPARγ), leptin (LEP), and adiponectin (ADIPO) levels in obese and insulin-resistant children compared with healthy controls. METHODS: Fifty-two children with obesity and insulin resistance (IR) and 33 age-matched healthy controls were included. The patient group received metformin for three months alongside lifestyle advice. Anthropometric data and the serum levels of Zn, ZAG, PPARγ, LEP, and ADIPO were measured before and after treatment. The outcomes were also analyzed on the basis of weight change. RESULTS: At baseline, the obesity group presented lower ZAG and ADIPO and higher LEP and IR indices than the control group did (p < 0.001). After treatment, BMI, insulin, HOMA-IR, and HDL-C improved. The serum Zn, ZAG, ADIPO, and LEP levels increased significantly (p < 0.05), whereas the PPARγ level remained unchanged. Although 73% had lost weight, 27% had gained weight. In the weight-gain group, both LEP and ADIPO increased, suggesting a weight-independent adipokine response to metformin. CONCLUSION: Metformin led to short-term improvements in metabolic and adipokine profiles in children with obesity and IR. The increase in ADIPO, even among those who gained weight, may reflect the potential weight-independent effect of metformin on insulin sensitivity. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT06266598.…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.